Après-demain is the holding company of the Debiopharm group, a Lausanne-based life science group developing cancer treatments. Après-demain’s main role is to diversify the Group’s assets through 3 main investment fields : Liquid assets, Real estate, Private Equity & Debt.
The Direct Private Equity & Debt team invests minority equity tickets from 10 to 100 mCHF/€ and private debt tickets from 3 to 10m CHF/€. The geographical focus is Western Europe, particularly Switzerland and France.

-

-

-

15-20

Axis, Crouzet, Ilmatar, Acteon, Hoppen, Rigoni di Asiago, CLS, Destia, Haut-Lac, Little Green House, BPA Solutions, ...

2005

Family Office

Buyout - Buyin, Delisting, Expansion - Development Capital, Mezzanine - Bridge Finance

All

France, Switzerland, Western Europe

Equity Financing, Loans, Mezzanine

CHF

3-100m

-

-

-